NCT03679598 - Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 8, 2019

Primary Completion Date

November 30, 2023

Study Completion Date

December 1, 2023

Conditions

Alpha-1 Antitrypsin Deficiency (AATD)Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I MutationsEmphysema or COPD

Interventions

DRUG

Alvelestat (MPH966)

Alvelestat was developed as treatment for lung diseases like Chronic Obstructive Pulmonary Disease. Alevelestat works by blocking certain proteins in the body that are responsible for inflammation and damage to the lungs that can lead to COPD symptoms.

OTHER

Placebo

Placebo is a pill or tablet that does not contain any study drug.

Trial Locations (10)

10032

Columbia University, New York

19140

Temple University, Philadelphia

27517

University of North Carolina at Chapel Hill, Chapel Hill

35294

The University of Alabama at Birmingham Lung Health Center, Birmingham

44195

Cleveland Clinic, Cleveland

75708

The University of Texas Health Science Center at Tyler, Tyler

80206

National Jewish Health, Denver

84108

University of Utah, Salt Lake City

90095

UCLA, Los Angeles

29425-6300

Medical University of South Carolina, Charleston